BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spadaccini M, D'Alessio S, Peyrin-Biroulet L, Danese S. PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. Int J Mol Sci. 2017;18. [PMID: 28617319 DOI: 10.3390/ijms18061276] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Lourenço EMG, Fernandes JM, Carvalho VF, Grougnet R, Martins MA, Jordão AK, Zucolotto SM, Barbosa EG. Identification of a Selective PDE4B Inhibitor From Bryophyllum pinnatum by Target Fishing Study and In Vitro Evaluation of Quercetin 3-O-α-L-Arabinopyranosyl-(1→2)-O-α-L-Rhamnopyranoside. Front Pharmacol 2019;10:1582. [PMID: 32038254 DOI: 10.3389/fphar.2019.01582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Li H, Fan C, Feng C, Wu Y, Lu H, He P, Yang X, Zhu F, Qi Q, Gao Y, Zuo J, Tang W. Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity. Br J Pharmacol 2019;176:2209-26. [PMID: 30883697 DOI: 10.1111/bph.14667] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
3 Marafini I, Troncone E, Salvatori S, Monteleone G. TGF-β activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases. Pharmacol Res 2020;155:104757. [PMID: 32194176 DOI: 10.1016/j.phrs.2020.104757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Iaia N, Rossin D, Sottero B, Venezia I, Poli G, Biasi F. Efficacy of theobromine in preventing intestinal CaCo-2 cell damage induced by oxysterols. Archives of Biochemistry and Biophysics 2020;694:108591. [DOI: 10.1016/j.abb.2020.108591] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
5 Li H, Zuo J, Tang W. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Front Pharmacol 2018;9:1048. [PMID: 30386231 DOI: 10.3389/fphar.2018.01048] [Cited by in Crossref: 129] [Cited by in F6Publishing: 111] [Article Influence: 32.3] [Reference Citation Analysis]
6 He W, Kapate N, Shields CW 4th, Mitragotri S. Drug delivery to macrophages: A review of targeting drugs and drug carriers to macrophages for inflammatory diseases. Adv Drug Deliv Rev 2020;165-166:15-40. [PMID: 31816357 DOI: 10.1016/j.addr.2019.12.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
7 Potdar AA, Li D, Haritunians T, VanDussen KL, Fiorino MF, Liu TC, Stappenbeck TS, Fleshner P, Targan SR, McGovern DPB, Bilsborough J. Ileal Gene Expression Data from Crohn's Disease Small Bowel Resections Indicate Distinct Clinical Subgroups. J Crohns Colitis 2019;13:1055-66. [PMID: 30877309 DOI: 10.1093/ecco-jcc/jjz021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Afra TP, Razmi TM, Dogra S. Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule. Indian Dermatol Online J 2019;10:1-12. [PMID: 30775293 DOI: 10.4103/idoj.IDOJ_437_18] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
9 Picchianti-Diamanti A, Spinelli FR, Rosado MM, Conti F, Laganà B. Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases. Int J Mol Sci 2021;22:2638. [PMID: 33807944 DOI: 10.3390/ijms22052638] [Reference Citation Analysis]
10 Friedrich M, Pohin M, Powrie F. Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. Immunity 2019;50:992-1006. [DOI: 10.1016/j.immuni.2019.03.017] [Cited by in Crossref: 131] [Cited by in F6Publishing: 120] [Article Influence: 43.7] [Reference Citation Analysis]
11 Yoo JH, Donowitz M. Intestinal enteroids/organoids: A novel platform for drug discovery in inflammatory bowel diseases. World J Gastroenterol 2019; 25(30): 4125-4147 [PMID: 31435168 DOI: 10.3748/wjg.v25.i30.4125] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
12 Perez-Sanchez C, Barbera Betancourt A, Lyons PA, Zhang Z, Suo C, Lee JC, McKinney EF, Modis LK, Ellson C, Smith KGC. miR-374a-5p regulates inflammatory genes and monocyte function in patients with inflammatory bowel disease. J Exp Med 2022;219:e20211366. [PMID: 35363256 DOI: 10.1084/jem.20211366] [Reference Citation Analysis]
13 Han L, Sayyid ZN, Altman RB. Modeling drug response using network-based personalized treatment prediction (NetPTP) with applications to inflammatory bowel disease. PLoS Comput Biol 2021;17:e1008631. [PMID: 33544718 DOI: 10.1371/journal.pcbi.1008631] [Reference Citation Analysis]
14 Dumortier C, Charlet R, Bettaieb A, Jawhara S. H89 Treatment Reduces Intestinal Inflammation and Candida albicans Overgrowth in Mice. Microorganisms 2020;8:E2039. [PMID: 33352792 DOI: 10.3390/microorganisms8122039] [Reference Citation Analysis]
15 Na YR, Stakenborg M, Seok SH, Matteoli G. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nat Rev Gastroenterol Hepatol. 2019;16:531-543. [PMID: 31312042 DOI: 10.1038/s41575-019-0172-4] [Cited by in Crossref: 142] [Cited by in F6Publishing: 141] [Article Influence: 47.3] [Reference Citation Analysis]
16 Ben Ghezala I, Charkaoui M, Michiels C, Bardou M, Luu M. Small Molecule Drugs in Inflammatory Bowel Diseases. Pharmaceuticals (Basel) 2021;14:637. [PMID: 34209234 DOI: 10.3390/ph14070637] [Reference Citation Analysis]
17 Song Z, Huang YY, Hou KQ, Liu L, Zhou F, Huang Y, Wan G, Luo HB, Xiong XF. Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis. J Med Chem 2022. [PMID: 35188767 DOI: 10.1021/acs.jmedchem.1c02058] [Reference Citation Analysis]
18 Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V. Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs 2019;79:1321-35. [PMID: 31317509 DOI: 10.1007/s40265-019-01169-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
19 Shi J, Ma W, Tang H. Research progress of phosphodiesterase inhibitors in inflammatory bowel disease treatment. Zhejiang Da Xue Xue Bao Yi Xue Ban 2021;50:659-65. [PMID: 34986542 DOI: 10.3724/zdxbyxb-2021-0170] [Reference Citation Analysis]
20 Su HJ, Chiu YT, Chiu CT, Lin YC, Wang CY, Hsieh JY, Wei SC. Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates. J Formos Med Assoc. 2019;118:1083-1092. [PMID: 30054112 DOI: 10.1016/j.jfma.2018.07.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
21 Na SY, Moon W. Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease. Gut Liver. 2019;13:604-616. [PMID: 31195433 DOI: 10.5009/gnl19019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
22 Raja TW, Veeramuthu D, Savarimuthu I, Al-Dhabi NA. Current Trends in the Treatment of Systemic Lupus Erythematosus. Curr Pharm Des 2020;26:2602-9. [PMID: 32066358 DOI: 10.2174/1381612826666200211122633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
23 Al-Dwairi A, Alqudah TE, Al-Shboul O, Alqudah M, Mustafa AG, Alfaqih MA. Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate/nuclear factor-κB pathway in vitro. J Inflamm Res 2018;11:95-109. [PMID: 29593427 DOI: 10.2147/JIR.S152835] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
24 Luchowska-Stańska U, Morgan D, Yarwood SJ, Barker G. Selective small-molecule EPAC activators. Biochem Soc Trans 2019;47:1415-27. [PMID: 31671184 DOI: 10.1042/BST20190254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
25 Lucaciu LA, Seicean R, Seicean A. Small molecule drugs in the treatment of inflammatory bowel diseases: which one, when and why? - a systematic review. Eur J Gastroenterol Hepatol 2020;32:669-77. [PMID: 32282548 DOI: 10.1097/MEG.0000000000001730] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Shivaji UN, Nardone OM, Cannatelli R, Smith SC, Ghosh S, Iacucci M. Small molecule oral targeted therapies in ulcerative colitis. Lancet Gastroenterol Hepatol 2020;5:850-61. [PMID: 32171056 DOI: 10.1016/S2468-1253(19)30414-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
27 Li Y, Chen J, Bolinger AA, Chen H, Liu Z, Cong Y, Brasier AR, Pinchuk IV, Tian B, Zhou J. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:S38-62. [PMID: 34791293 DOI: 10.1093/ibd/izab190] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Takeno M. Positioning of apremilast in treatment of Behçet’s disease. Modern Rheumatology 2020;30:219-24. [DOI: 10.1080/14397595.2019.1696504] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Sun Q, Arif M, Chi Z, Li G, Liu CG. Macrophages-targeting mannosylated nanoparticles based on inulin for the treatment of inflammatory bowel disease (IBD). Int J Biol Macromol 2021;169:206-15. [PMID: 33340633 DOI: 10.1016/j.ijbiomac.2020.12.094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]